Resources from the same session
LBA15 - Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Presenter: David Miles
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA16 - IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
Presenter: Leisha Emens
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA17 - ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
Presenter: Aditya Bardia
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA18 - Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)
Presenter: Fabrice André
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
273O - nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer
Presenter: Erika Hamilton
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA15 and LBA16
Presenter: Lisa Carey
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Lisa Carey
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Webcast
Q&A and live discussion
Presenter: Lisa Carey
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Webcast